Response Biomedical Corp. (fka RPBIF)

[urche]

TSX listing---good but worrisome PR

What is not stated is what worries me.

From the PR today:
VANCOUVER, Dec. 20 /CNW/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that its common shares have been approved for listing on the Toronto Stock Exchange (TSX) and will no longer trade on the TSX Venture Exchange. Trading on the TSX will commence tomorrow, Friday, December 21, 2007 under the symbol "RBM". Response Biomedical Corporation was initially listed and began trading on the TSX Venture Exchange on April 9, 1984.

"Our listing on the TSX provides access to a broader base of potential investors and supports our strategic growth objectives," said S. Wayne Kay, CEO. "We believe our most significant near-term business milestone is the anticipated signing of a global marketing partner for our cardiovascular line of RAMP(R) rapid tests. Finding the right strategic partner in the cardiovascular area has been my primary focus since joining the Company and we are in active discussions to have this completed as soon as reasonably possible."

The fact that the partnership is the next milestone on the horizon gives me a sense of foreboding that the long awaited approval for the Response NT pro-BNP test is still mired in FDA delays. The company has been strangely, publicly quiet about the delay in approval. I learned that they have amended the filing in ways that would give the test some marketing advantages. But, still, I don''t like the indefinite delay and lack of news--gives me a sense of foreboding.

urche